Sort
17,828 grants matching “crispr”
Development of Bone Marrow Organoid System to Study RUNX1-Familial Platelet Disorder with Associated Myeloid Malignancy (RUNX1-FPD/MM)
$178,000Alan B. Cantor · Boston Children'S Hospital · R03 · FY2025 · TR
Novel genetic dependencies in VRK2 methylated glioblastoma multiforme
$178,000William C Hahn · Dana-Farber Cancer Inst · R03 · FY2020 · TR
Somatic Engineering-based Models of Pancreatic Cancer
$177,884Monte Meier Winslow · Stanford University · R21 · FY2016 · CA
Engineering CRISPR constructs to elucidate the causal contribution of cell-type specific, gene-targeted CREB binding to the pathogenesis of drug abuse
$177,770Peter James Hamilton · Icahn School Of Medicine At Mount Sinai · K99 · FY2018 · DA
High Throughput Screening Shared Resource
$177,706Bruce Arthur Posner · Ut Southwestern Medical Center · P30 · FY2022 · CA
High Throughput Screening Shared Resource
$177,706Bruce Arthur Posner · Ut Southwestern Medical Center · P30 · FY2024 · CA
High Throughput Screening Shared Resource
$177,706Bruce Arthur Posner · Ut Southwestern Medical Center · P30 · FY2023 · CA
High Throughput Screening Shared Resource
$177,706Bruce Arthur Posner · Ut Southwestern Medical Center · P30 · FY2021 · CA
Transgenic & Knock-out Mouse
$177,418Pamela L Mellon · University Of California, San Diego · P30 · FY2021 · DK
New Therapeutic Targets in Small Cell Lung Cancer that are Epistatic or Synthetic Lethal with pRB Loss
$177,120Matthew Gilbert Oser · Dana-Farber Cancer Inst · K08 · FY2017 · CA
New Therapeutic Targets in Small Cell Lung Cancer that are Epistatic or Synthetic Lethal with pRB Loss
$177,120Matthew Gilbert Oser · Dana-Farber Cancer Inst · K08 · FY2021 · CA
New Therapeutic Targets in Small Cell Lung Cancer that are Epistatic or Synthetic Lethal with pRB Loss
$177,120Matthew Gilbert Oser · Dana-Farber Cancer Inst · K08 · FY2018 · CA
Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer
$177,120Andrew James Aguirre · Dana-Farber Cancer Inst · K08 · FY2017 · CA
Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer
$177,120Andrew James Aguirre · Dana-Farber Cancer Inst · K08 · FY2020 · CA
Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer
$177,120Andrew James Aguirre · Dana-Farber Cancer Inst · K08 · FY2018 · CA
Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer
$177,120Andrew James Aguirre · Dana-Farber Cancer Inst · K08 · FY2021 · CA
Elucidating KRAS-specific vulnerabilities in pancreatic cancer
$177,120Mandar Deepak Muzumdar · Dana-Farber Cancer Inst · K08 · FY2016 · CA
New Therapeutic Targets in Small Cell Lung Cancer that are Epistatic or Synthetic Lethal with pRB Loss
$177,120Matthew Gilbert Oser · Dana-Farber Cancer Inst · K08 · FY2019 · CA
Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer
$177,120Andrew James Aguirre · Dana-Farber Cancer Inst · K08 · FY2019 · CA
New Therapeutic Targets in Small Cell Lung Cancer that are Epistatic or Synthetic Lethal with pRB Loss
$177,120Matthew Gilbert Oser · Dana-Farber Cancer Inst · K08 · FY2020 · CA
NANOPARTICLE-BASED CRISPR SCREEN TO IDENTIFY GENETIC REGULATORS OF CHEMORESISTANCE
$177,000Children'S Hospital Corporation, The · · FY2021 · Department of the Army
Overcoming drug resistance using small molecule activators of protein phosphatase 2A
$176,961Jennifer D Black · University Of Nebraska Medical Center · R21 · FY2023 · CA
Development of a novel genome targeting technology using rational design and continuous evolution.
$176,875Jesse Bruce Owens · University Of Hawaii At Manoa · R21 · FY2019 · GM
Transgenic and Targeted Mutagenesis Laboratory Shared Resource
$176,584Rajeshwar B Awatramani · Northwestern University At Chicago · P30 · FY2024 · CA
Transgenic and Targeted Mutagenesis Laboratory Shared Resource
$176,584Rajeshwar B Awatramani · Northwestern University At Chicago · P30 · FY2023 · CA